New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored programming, featuring Acurx Pharmaceuticals. This compelling episode follows the incredible journey of co-founders David P. Luci, Robert J. DeLuccia, and Robert G. Shawah - from their college days to building and exiting successful pharmaceutical companies, and ultimately coming together to launch Acurx Pharmaceuticals.
The series explores the vision, perseverance, and expertise that led them to develop groundbreaking antibiotics, addressing urgent global health challenges with innovative treatments.
About New to The Street
New to The Street is a premier televised business program that has been showcasing innovative companies and industry leaders for over 15 years. Airing as sponsored programming on Fox Business, Bloomberg, and major networks, the show provides national TV exposure, earned media coverage, and strategic outdoor advertising. With over 2.4 million YouTube subscribers, New to The Street delivers compelling content that reaches investors, consumers, and business leaders worldwide.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. The company's Gram-positive selective spectrum (GPSS®) technology targets DNA polymerase IIIC (pol IIIC), an essential bacterial enzyme, effectively stopping bacterial replication and leading to cell death.
Acurx's lead product candidate, ibezapolstat, is Phase 3 ready for the treatment of Clostridioides difficile (C. difficile) infection, with international clinical trials set to begin this year. The company is also advancing a novel oral antibiotic for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and developing a parallel program for inhaled anthrax treatment.
Meet the Founding Team: From College to Biotech Success
David P. Luci - Co-Founder, President & CEO
David P. Luci began his career in finance and corporate law, before moving into biotech leadership. He co-founded Acurx Pharmaceuticals after serving as President & CEO of Dipexium Pharmaceuticals (Nasdaq:DPRX), where he successfully led its $69 million merger with PLx Pharma Inc. (Nasdaq:PLXP). With a background in healthcare finance at Ernst & Young LLP and corporate law at Paul Hastings LLP, Mr. Luci has been a driving force in biotech innovation and M&A transactions.
Robert J. DeLuccia - Co-Founder, Executive Chairman
Robert J. DeLuccia's executive leadership and marketing expertise have been instrumental in the growth of multiple pharmaceutical companies. Before co-founding Acurx, he was Executive Chairman of Dipexium Pharmaceuticals, leading it through a successful exit. He previously served as CEO of Immunomedics, Inc., President of Sterling Winthrop, and held senior leadership roles at Pfizer. His strategic vision and business development acumen have helped shape Acurx's long-term success.
Robert G. Shawah, CPA - Co-Founder & Chief Financial Officer
Robert G. Shawah is the financial backbone of Acurx Pharmaceuticals. With over 30 years of experience in finance, accounting, and corporate governance, he previously served as Chief Accounting Officer at Dipexium Pharmaceuticals, helping steer the company through its acquisition. His extensive background in financial management and operations includes leadership roles at Arthur Andersen PC and WR Grace & Co.
A Story of Innovation, Grit, and Success
The Visionaries Series offers a rare glimpse into the founding story of Acurx Pharmaceuticals, from college friendships and early career moves to their breakthroughs in biotech and successful pharma exits. The episode highlights how their combined expertise in finance, corporate strategy, and drug development led to the creation of a company poised to revolutionize antibiotic treatments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
AstroNova Announces Segment Leadership Promotions to Drive Execution of Growth Strategy
WEST WARWICK, R.I., June 12, 2025--(BUSINESS WIRE)--AstroNova, Inc. (Nasdaq: ALOT), a leading innovator in data visualization technology, today announced the promotion of Jorik Ittmann to Senior Vice President of Product Identification. Jorik joins Tom Carll, who was promoted to Senior Vice President of Aerospace, at the end of the first quarter as the leaders of AstroNova's two segments. Both Jorik and Tom will continue to report directly to President and Chief Executive Officer Gregory Woods. Mr. Ittmann and Mr. Carll will be responsible for driving the sales, marketing and operational execution of the Product Identification and Aerospace segments, respectively. Both executives are responsible for and will be compensated on the financial performance of their segments, reinforcing AstroNova's commitment to driving accountability and long-term growth across the organization. Jorik Ittmann, who joined AstroNova in September 2024 as Vice President of Commercial Operations for the Product Identification segment, brings more than 20 years of global sales and business development experience across the healthcare and printing technology industries. Prior to AstroNova, he held senior roles at Zebra Technologies and Health Link Solutions, where he led revenue growth, expanded international markets, and strengthened sales teams. Tom Carll has been a vital member of AstroNova's leadership team since joining the company in 1989. Over the course of his career, he has held a variety of senior positions, including Sales Engineer, National Sales Manager for the Test & Measurement group, and leadership roles within the Aerospace segment since its inception in 2004. "Jorik and Tom have played critical roles in advancing our Product Identification and Aerospace businesses in the last six months and this organizational structure reflects the confidence we have in their continued executional focus," said Greg Woods, President and CEO of AstroNova. "Their expanded responsibilities and new simplified reporting structure will better align execution, support segment growth, and position us to unlock value for our customers and shareholders." About AstroNova AstroNova (Nasdaq: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes and services a broad range of products that acquire, store, analyze, and present data in multiple formats. Its strategy is to drive profitable growth through innovative new technologies, building its installed base to expand recurring revenue while strategically sourcing its replacement products. The Product Identification segment provides a wide array of digital, end-to-end product marking and identification solutions, including hardware, software, and supplies for OEMs, commercial printers, and brand owners. The Aerospace segment provides products designed for airborne printing solutions, avionics, and data acquisition. Aerospace products include flight deck printing solutions, networking hardware, and specialized aerospace-grade supplies. Data acquisition systems are used in research and development, flight testing, missile and rocket telemetry, production monitoring, power, and maintenance applications. For more information please visit: Important Additional Information In connection with its 2025 Annual Meeting of Shareholders, AstroNova has filed a definitive proxy statement with the SEC and caused it to be mailed, together with an annual report and proxy card, to each of our shareholders. The proxy statement and a copy of the other materials that we file with the SEC from time to time, including our Annual Report on Form 10-K, as amended, for the fiscal year ended January 31, 2025, may be obtained free of charge via the Internet at and through the Investor Relations page of our corporate website, In addition, investors and security holders may obtain free copies of the proxy statement, the annual report and other proxy materials by directing a written request to ALOTproxy@ The proxy statement and other relevant materials we have made or will make available contain important information about the director nominees and the other matters to be voted upon by shareholders at the 2025 Annual Meeting of Shareholders. AstroNova urges shareholders to read the proxy statement, and any other relevant materials we make available, before making any decision with respect to the matters to be voted upon at the 2025 Annual Meeting of Shareholders, including the election of directors. View source version on Contacts Investor/Media Contact:Deborah Pawlowski, IRC, Alliance AdvisorsEmail: dpawlowski@ Phone: 716.843.3908
Business Wire
8 minutes ago
- Business Wire
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under 'Events' in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and unique PIN to access the call. Those who plan on participating are advised to join 15 minutes prior to the start time. A webcast replay of the call will be available on Vistagen's website about 24 hours after the end of the live conference call and will be accessible for at least 30 days. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists to peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen's neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at
Business Wire
13 minutes ago
- Business Wire
GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare's proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagnostic confidence, streamline workflows, and support the future of personalized medicine. 'In today's rapidly evolving healthcare landscape, operational efficiency and seamless collaboration are not just goals — they're the cornerstone to success. That's why we aim to provide tools that can help enhance providers' confidence in decision making and support patients in receiving personalized care,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We are committed to delivering technology that unifies data across systems and organizations, breaking down workflow barriers to help drive better clinical outcomes and elevate the standard of patient care.' New capabilities now available to GE HealthCare, MIM Software customers Now featuring dedicated post-processing tools for GE HealthCare systems, MIM Encore helps deliver excellent image quality with minimal effort, streamlining everyday nuclear medicine and cardiology workflows. Users can expect high image quality with minimal effort, along with automated read preparation, structured reporting, and flexible interpretation tools for PET/CT, SPECT/CT, and multi-modality fusion — all in a single platform. MIM Encore empowers clinicians and researchers to help deliver fast, accurate diagnoses, and onboard users quickly, for efficiencies and consistencies in work and communication between clinicians. 'Customers are telling us that this pairing is exactly what users have been looking for. The combined solution enables streamlined, accurate reading of images, supports quantitative analysis out of the box, and helps eliminate manual entries,' says Andrew Nelson, CEO, MIM Software, a GE HealthCare Company. 'As we continue to evolve our vertically integrated products based on user input, we remain focused on creating a user-friendly, vendor-neutral, future ready experience designed to scale with advanced molecular imaging needs.' With easy adoption across departments and roles — as well as few manual steps — MIM Encore adds resolution recovery and image-enhancing tools tailored for GE HealthCare scanners, streamlining workflows while helping elevate diagnostic confidence across care areas. Oncology: MIM Software's tools, now paired with GE HealthCare systems, simplify SPECT image processing with reconstruction and configurable enhancements, including resolution recovery, attenuation and scatter correction, advanced filtering, and motion correction. As a result, clinicians can view dynamic and static scans, share images easily, and access advanced quantitation tools — helping deliver clear insights with less manual effort. Cardiology: GE HealthCare's cardiac imaging is now even stronger with MIM technology's advanced PET and SPECT tools, enabling fast, high-quality reconstructions and quantitative analysis. Features like motion correction, automated quality checks, and intuitive displays help deliver accurate and efficient cardiac care. With support for key radiotracers and advanced algorithms like Evolution for Cardiac — developed at Johns Hopkins and University of North Carolina — MIM Encore is designed to deliver high-quality images at reduced acquisition times or doses i. Neurology: As a leader in neurodegenerative imaging, GE HealthCare with MIM technology now offers reconstruction workflows with 3D rendering and advanced corrections. As a result, clinicians benefit from consistent, high-quality images and easy-to-use tools for confident diagnosis, and assistance in treatment planning and evaluation. Also new, GE HealthCare's Effortless Workflow seamlessly integrates with MIM Encore, enabling clinicians to manage rising caseloads with intuitive interfaces, customizable displays, and automation that can help bridge experience gaps and reduces burnout. GE HealthCare acquired MIM Software in 2024, bringing together two industry leaders with expertise in multi-modality imaging, quantitation, workflow automation and molecular imaging. For more information on GE HealthCare's molecular imaging portfolio – including MIM Encore – please visit and SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
